Mouse Anti-MAPT Recombinant Antibody (clone AT8) (CAT#: PABL-340)

Figure 1 Immunocytochemistry of representative tau pathology in human AD brain and JNPL3 Tg mice with new antibodies 2D1 and 7F2.

Immuno-reactivity of previously characterized phospho-tau antibodies AT8 and new tau antibodies 2D1 or 7F2 in the hippocampus of a control individual or a subject with AD, and in the spinal cord of 12 month old nTg and JNPL3 Tg mice. Arrows indicating NFTs in human brain or NFT-like inclusion pathology in JNPL3 mice. Asterisk depicting dystrophic neurites within senile plaques. Bar = 100 μm, and 200 μm for insets

Strang, K. H., Goodwin, M. S., Riffe, C., Moore, B. D., Chakrabarty, P., Levites, Y.,... & Giasson, B. I. (2017). Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau. Acta neuropathologica communications, 5(1), 58.

Figure 2 Characterization of the novel tau antibodies in detecting biochemically sarkosyl-insoluble tau in human brain lysates from AD patients.

Immunoblotting analysis of the sarkosyl-insoluble fraction from the temporal cortex of human AD cases (n = 3) and control cases (CTR; n = 2). Equal amounts of proteins (10 μg) from each sample was resolved onto 10% polyacrylamide gels and analyzed by immunoblotting with antibody indicated above blot

Strang, K. H., Goodwin, M. S., Riffe, C., Moore, B. D., Chakrabarty, P., Levites, Y.,... & Giasson, B. I. (2017). Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau. Acta neuropathologica communications, 5(1), 58.

Figure 3 Analysis of tau signal with commercial monoclonal antibodies by Western blotting.

The proteins were extracted form the cortex of 3 mouse lines: control mice (WT and Hypothermic), Tau KO mice and 3xTg mice with n = 3 for each group. Proteins were extracted with SDS-PAGE and then identified with the following monoclonal antibody AT8. Normal anti-mouse (1) and Mouse TrueBlot ULTRA (2) secondary antibodies were used to detect primary antibodies.

Petry, F. R., Pelletier, J., Bretteville, A., Morin, F., Calon, F., Hébert, S. S.,... & Planel, E. (2014). Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions. PloS one, 9(5), e94251.

Figure 4 Anti-Tau Antibodies Strongly Decreased AT8 Staining in P301S Mouse Brain.

Representative coronal sections of PBS (A)-, HJ3.4 antibody (B)-, HJ8.5 antibody (C)-, HJ9.3 antibody (D)-, and HJ9.4 antibody (E)-treated 9-month-old P301S mice stained with biotinylated AT8 antibody in regions including the piriform cortex and amygdala. Scale bar represents 250 μm. Insets in (A)–(E) show the higher magnification of biotinylated AT8 antibody staining of phosphorylated tau, scale bar represents 50 μm.

Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E.,... & Holtzman, D. M. (2013). Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron,80(2), 402-414.

Figure 5 Certain Anti-Tau Antibodies Strongly Decrease AT8 Staining in P301S Mouse Brain.

Percent of the area covered by biotinylated AT8 staining of abnormally phosphorylated tau in piriform cortex (A), entorhinal cortex (B), amygdala (C), and hippocampus CA1 region (D) in mice treated with the anti-tau antibodies HJ8.5 (n = 13), HJ9.3 (n = 15), HJ9.4 (n= 13), the anti-Aβ antibody, HJ3.4 (n = 8), or PBS (n = 16) in 9-month-old P301S mice. There was reduced AT8 staining in several different brain regions in the anti-tau antibody-treated mice compared to PBS or HJ3.4 antibody-treated mice. HJ8.5 had the largest effects.

Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E.,... & Holtzman, D. M. (2013). Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron,80(2), 402-414.